AI HypeAI hype is scary real. I think AI is probably already hyping itself. Long live our new rulers.
A break above 0.53 would bring more strength. Pattern could be a rare Wolfe Wave. Time will tell.
−3.48USD
−13.98 MUSD
1.78 MUSD
3.91 M
About Predictive Oncology Inc.
Sector
Industry
CEO
Raymond F. Vennare
Website
Headquarters
Pittsburgh
Employees (FY)
34
Founded
2002
ISIN
US74039M3097
FIGI
BBG000PVXTF7
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.
POAI 15 min Scalpers editiontest
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, Skyline, Soluble, and
POAI bullish wave 3 startedSeems we have corrected wave (2) now and subwave 1 of (3) is initiated
High risk trade
POAI 2HRtest
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, Skyline, Soluble, and
POAI **ON WATCH** 88% BORROW RATEAll,
Add POAI to your watchlist and watch the borrow rate. It is currently sitting at 88% meaning a short squeeze could be imminent. Definitely have to be careful with short squeezes. Need breakouts, news, volume to pull of a short squeeze so sometimes these cheaper stocks with not so good or bad f
POAI moving above $1.06 towards $1.40The Hull Moving Average is following the Fib circles, the Chaikin Money Flow appears to be crossing up and the nice arc makes us think this stock is going LONG.
Some action is coming ?!#NewsPlay $POAI seems doesn't want to hit its support for this channel. Which is a very bullish signal.
Bollinger getting tight, RSI and MACD turning up and crossing (respectively).
Even Volume is coming. There may be some action very soon.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where POAI is featured.
Frequently Asked Questions
The current price of POAI is 1.20 USD — it has increased by 4.34% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Predictive Oncology Inc. stocks are traded under the ticker POAI.
Predictive Oncology Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
POAI stock is 18.96% volatile and has beta coefficient of 2.50. Check out the list of the most volatile stocks — is Predictive Oncology Inc. there?
POAI earnings for the last quarter are −1.00 USD per share, whereas the estimation was −0.20 USD resulting in a −400.00% surprise. The estimated earnings for the next quarter are −1.20 USD per share. See more details about Predictive Oncology Inc. earnings.
Predictive Oncology Inc. revenue for the last quarter amounts to 455.83 K USD despite the estimated figure of 4.00 M USD. In the next quarter revenue is expected to reach 500.00 K USD.
Yes, you can track Predictive Oncology Inc. financials in yearly and quarterly reports right on TradingView.
POAI stock has fallen by 35.48% compared to the previous week, the month change is a 53.31% fall, over the last year Predictive Oncology Inc. has showed a 78.94% decrease.
POAI net income for the last quarter is −3.48 M USD, while the quarter before that showed −3.16 M USD of net income which accounts for −9.86% change. Track more Predictive Oncology Inc. financial stats to get the full picture.
Today Predictive Oncology Inc. has the market capitalization of 4.67 M, it has decreased by 6.83% over the last week.
No, POAI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, POAI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Predictive Oncology Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 34.00 employees. See our rating of the largest employees — is Predictive Oncology Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Predictive Oncology Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Predictive Oncology Inc. stock shows the strong sell signal. See more of Predictive Oncology Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Predictive Oncology Inc. EBITDA is −13.18 M USD, and current EBITDA margin is −740.52%. See more stats in Predictive Oncology Inc. financial statements.